Literature DB >> 28770373

Early predictive factors of disability in CIDP.

Emanuele Spina1, Antonietta Topa1, Rosa Iodice1, Stefano Tozza1, Lucia Ruggiero1, Raffaele Dubbioso1, Marcello Esposito1, Dario Bruzzese2, Lucio Santoro1, Fiore Manganelli3.   

Abstract

The objective of this study was to identify early clinical, biochemical and electrophysiological prognostic factors of disability in CIDP. We evaluated a dataset from 60 CIDP patients that included sex, age of onset, type of onset, phenotype, disease duration, response to treatment, disability at the time of diagnosis assessed using the modified Rankin Scale (baseline mRS), cerebrospinal fluid protein levels and electrophysiological data. All patients had clinical assessment of disability through the mRS within the last 6 months (last mRS) before enrollment in the study. Stepwise forward logistic regression model was applied to evaluate the impact of clinical, biochemical and electrophysiological parameters on the last mRS, considered as binary outcome (absence or presence of severe disability, i.e., <4/≥4 mRS). Moreover, we used Spearman's rank correlation coefficient to evaluate the relationship between disease duration and last mRS. We observed a significant relationship between last mRS and baseline mRS [p = 0.015, z = 2.44, OR 5.15 (CI 1.38-19.22)] and age of onset [p = 0.017, z = 2.39, OR 1.13 (CI 1.02-1.27) per additional year of age of onset]. There was no correlation between disease duration and last mRS. Our data suggest that a worse clinical status at the beginning of disease and an older age at onset may be negative prognostic factors of long-term disability independent from disease duration.

Entities:  

Keywords:  CIDP; Disability; Dysimmune neuropathies; Neurophysiology; Polyradiculoneuropathy

Mesh:

Year:  2017        PMID: 28770373     DOI: 10.1007/s00415-017-8578-9

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  31 in total

1.  Chronic inflammatory demyelinating polyradiculoneuropathy: long-term course and treatment of 60 patients.

Authors:  A Sghirlanzoni; A Solari; C Ciano; C Mariotti; E Fallica; D Pareyson
Journal:  Neurol Sci       Date:  2000-02       Impact factor: 3.307

2.  Chronic inflammatory demyelinating polyneuropathy: clinical features and response to treatment in 67 consecutive patients with and without a monoclonal gammopathy.

Authors:  K C Gorson; G Allam; A H Ropper
Journal:  Neurology       Date:  1997-02       Impact factor: 9.910

3.  Interobserver agreement for the assessment of handicap in stroke patients.

Authors:  J C van Swieten; P J Koudstaal; M C Visser; H J Schouten; J van Gijn
Journal:  Stroke       Date:  1988-05       Impact factor: 7.914

Review 4.  Updated assessment of the prevalence, spectrum and case definition of autoimmune disease.

Authors:  Scott M Hayter; Matthew C Cook
Journal:  Autoimmun Rev       Date:  2012-02-23       Impact factor: 9.754

Review 5.  Chronic inflammatory demyelinating polyradiculoneuropathy and variants: where we are and where we should go.

Authors:  Eduardo Nobile-Orazio
Journal:  J Peripher Nerv Syst       Date:  2014-03       Impact factor: 3.494

6.  Prognostic indicators for long-term disability in multiple sclerosis patients.

Authors:  Alfredo Damasceno; Felipe Von Glehn; Carlos Otávio Brandão; Benito Pereira Damasceno; Fernando Cendes
Journal:  J Neurol Sci       Date:  2012-10-13       Impact factor: 3.181

7.  A nationwide retrospective analysis on the effect of immune therapies in patients with chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  D Cocito; I Paolasso; G Antonini; L Benedetti; C Briani; C Comi; R Fazio; S Jann; S Matà; A Mazzeo; M Sabatelli; E Nobile-Orazio
Journal:  Eur J Neurol       Date:  2009-10-23       Impact factor: 6.089

8.  Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: a double blind, placebo controlled study.

Authors:  M Vermeulen; P A van Doorn; A Brand; P F Strengers; F G Jennekens; H F Busch
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-01       Impact factor: 10.154

9.  Long-term treatment of chronic inflammatory demyelinating polyradiculoneuropathy with plasma exchange or intravenous immunoglobulin.

Authors:  P P Choudhary; R A Hughes
Journal:  QJM       Date:  1995-07

10.  No prognostic value of routine cerebrospinal fluid biomarkers in a population-based cohort of 407 multiple sclerosis patients.

Authors:  Madlyne Becker; Clotilde Latarche; Emilie Roman; Marc Debouverie; Catherine Malaplate-Armand; Francis Guillemin
Journal:  BMC Neurol       Date:  2015-05-13       Impact factor: 2.474

View more
  2 in total

1.  Therapeutic Plasma Exchange as a Treatment for Autoimmune Neurological Disease.

Authors:  Ivana Nieto-Aristizábal; Álvaro J Vivas; Pablo Ruiz-Montaño; Cristian C Aragón; Iván Posso-Osorio; Jairo Quiñones; Julián Alejandro Rivillas; Gabriel J Tobón
Journal:  Autoimmune Dis       Date:  2020-07-31

2.  Pediatric CIDP: Diagnosis and Management. A Single-Center Experience.

Authors:  Małgorzata Łukawska; Anna Potulska-Chromik; Marta Lipowska; Dorota Hoffman-Zacharska; Beata Olchowik; Magdalena Figlerowicz; Karolina Kanabus; Edyta Rosiak; Anna Kostera-Pruszczyk
Journal:  Front Neurol       Date:  2021-07-02       Impact factor: 4.003

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.